Investor Presentation H1 2023
6
Investor presentation
First six months of 2023
Diabetes value market leadership increased by 1.7%-points to
32.7%
Novo Nordisk global diabetes value market shares
Diabetes value market leadership expansion
driven by the GLP-1 franchise
60%
-Diabetes
-GLP-1
-Insulin
54.8%
54.1%
51.5%
49.1%
50%
44.6%
44.0%
44.2%
44.3%
•
40%
32.7%
31.0%
29.1%
29.6%
30%
0% T
2020
2021
2022
2023
CER: Constant exchange rates; IO: International Operations; NAO: North America Operations
Note: Sales growth rates are at CER
Source: IQVIA MAT, May 2023 (Spot rate); Volume growth based on Moving Annual Total (MAT)
Diabetes care sales grew by 24% (CER) with global value
market share increase driven by GLP-1 market share gains in
both IO and NAO. Global diabetes care market volume growth
was -4%
• GLP-1 value market share has decreased by 0.7%-points in
the last 12 months
Estimated global GLP-1 share of total diabetes
prescriptions is ~5%
Novo NordiskⓇView entire presentation